


Our endeavour

Endure Enhance Excel



Disclaimer



Atul Ltd (Atul) may, from time to time, make written and oral forward-looking statements, in addition to the statements contained in the filings of the Company with BSE Ltd and National Stock Exchange of India Ltd, and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of it.

All information contained in this presentation has been prepared solely by Atul. The Company does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.





Chemicals and daily life


























More than 96% of all manufactured goods are directly enabled by chemistry

















Industries served



about Atul





founder Kasturbhai Lalbhai (1894 –1980)



first site spread across 1,300 acres

three dreams ... create wealth for rural India ... generate employment on a large scale ... make India self-reliant

> incorporation September 5, 1947



first company of India inaugurated by its first Prime Minister



economist Balwantrai Mazumdar (1902 – 1981)



chemical engineer Siddharth Lalbhai (1923 – 1998)



Profile





Entities



Atul Bioscience Ltd



DPD Ltd



Atul Rajasthan Date Palms Ltd



Amal Ltd



Atul Ltd

Rudolf Atul Chemicals Ltd



Valsad Institute of Medical Sciences Ltd



Atul Brasil Quimicos Ltda



Atul China Ltd



Atul Europe Ltd



Atul Ireland Ltd

Atul Foundation



Atul Middle-East FZ-LLC



Atul USA Inc









Atul Club



Atul Institute of Vocational Excellence



Sub-segments





Aromatics



Crop Protection – Retail



Pharmaceuticals



Bulk Chemicals and Intermediates



Colors



Polymers – Performance Materials



Crop Protection – Bulk Actives



Floras







There is no gain without struggle.

- Martin Luther King Junior












 $^{1}\,\mbox{expenditure}$ amount differs from that capitalised

² related only to LER project under implementation

₹ cr



Fitment to strategy why AkzoNobel and Atul formed Anaven



- AkzoNobel wanted local presence in the fast growing Indian market to increase its share
- Atul wanted to have forward integration of Cl₂ based products and backward integration for 2,4-D

What went well 2023-24



- two sub-segments generated higher PBT compared to 2022-23 (lower than the best achieved)
- both retail sub-segments turned PBT positive
- three subsidiary | associate companies generated higher PBT compared to 2022-23
- 5% increase in volume over 2022-23 on standalone basis
- % contribution maintained
- lower net working capital tie-up by 14 and 7 days on standalone and consolidated basis
- first patented formulation, Sindica, launched by Crop Protection Retail
- new process engineering laboratory commissioned
- Oracle ERP implemented across subsidiary, associate and JV entities
- five key commercial activities digitalised
- new state-of-the-art occupational health center started

What did not go well 2023-24



Internal

- delay in implementation of projects
- delay in reaching expected performance in product quality and production | sales volume
- unexpected breakdowns in manufacturing
- low capacity utilisation

External

- global supply chain impacted by geo-political tensions
- subdued demand in key consuming industries
 o destocking in chemical industry
- decrease in chemical prices
- pressure on margins
 - o finished goods prices fell more than raw materials prices
 - o absolute decrease in contribution per unit

Securing future ever changing



Sales

- CRM
- Planvisage

Manufacturing

- people productivity
- process efficiency

Technology

- debottlenecking
- project management

Research

- new products and formulations
- process engineering

Commercial

- iSourcing | iSupplier
- warehouse management

Finance

- Oracle ERP (across entities)
- robotic automation

Information technology

- pervade visualisation
- communication and collaboration

Human resources

- HR processes
- manpower planning



Values and attributes never changing

A A

Integrity



Understanding



Unity



Responsibility



Excellence



Continuous improvement



Bias for action



Attention to detail



Structured approach



Learning agility



Creativity

Atul Foundation





Education



Empowerment



Health



Relief

Infrastructure

Conservation



new initiatives in CSR



reached 10,224 students through 117 Adhyapikas



trained 23 Anujas to provide pre-primary education in anganwadis



educated 3,220 children through mobile science van



educated 781 health practitioners to take care of mothers and child during first 1,000 days



Atul Foundation Health Center



providing consultations through 4 in-house and 14 visiting doctors to the people from Atul and surrounding villages



World chemical market 2022

Euro bn

Country	Production	Imports	Exports	Consumption	Net imports
China	2,390	208	194	2,404	14
USA	606	147	170	583	-23
Germany	225	133	150	207	-18
Japan	227	52	80	199	-28
India	115	89	42	162	47
France	139	64	76	128	-11
South Korea	139	59	94	103	-36
World	5,622	1,922	1,744	5,800	

- share of China in global GDP 19% but in chemicals 43%
- share of China in global production up from 25.8% in 2010 to 42% in 2022
- share of India almost stagnant around 2.5% in the same period
- India ranked 7th in global production and 5th in consumption
- India the largest net importer of chemicals in the world



Indian chemical industry production versus consumption

Euro bn

Year	Production	Exports	Imports	Consumption
2018	102	28	48	121
2019	101	30	49	119
2020	88	27	42	104
2021	99	33	63	129
2022	115	42	89	162
CAGR	3%	11%	17%	7%

CAGR of consumption significantly higher than CAGR of production

atul

Chemical production

			% growth over PY
2020	2021	2022	2023
-0.2	4.1	-4.4	-13.2
-3.1	8.6	-9.9	-10.7
-1.3	5.7	-12.1	-10.4
-2.2	6.1	-6.3	-8.0
-12.2	5.1	-3.8	-6.4
0.0	3.6	1.1	-5.9
-4.9	4.2	2.2	-1.0
-5.4	8.0	4.2	0.1
7.4	7.1	-2.3	4.6
2.9	8.4	6.4	9.6
-0.5	7.3	1.5	2.3
	-0.2 -3.1 -1.3 -2.2 -12.2 0.0 -4.9 -5.4 7.4 2.9	-0.2 4.1 -3.1 8.6 -1.3 5.7 -2.2 6.1 -12.2 5.1 0.0 3.6 -4.9 4.2 -5.4 8.0 7.4 7.1 2.9 8.4	-0.2 4.1 -4.4 -3.1 8.6 -9.9 -1.3 5.7 -12.1 -2.2 6.1 -6.3 -12.2 5.1 -3.8 0.0 3.6 1.1 -4.9 4.2 2.2 -5.4 8.0 4.2 7.4 7.1 -2.3 2.9 8.4 6.4

Indian chemical production almost stagnant despite strong economy

domination of China going up despite all geopolitical issues

Trade deficit – Chapter 29

	1	2	1	f,	
4	2	L	C	4	r
-	C	-	-		

US\$ bn

Country		Imp	orts			Exp	orts			Trade	deficit	
Country	20-21	21-22	22-23	23-24	20-21	21-22	22-23	23-24	20-21	21-22	22-23	23-24
China	9.0	12.5	13.2	11.8	2.4	2.4	1.5	1.2	-6.6	-10.1	-11.7	-10.6
Others	10.7	16.0	15.7	15.5	15.5	19.6	19.9	17.8	4.8	3.6	4.2	2.3
Total	19.7	28.5	29.0	27.3	17.9	22.0	21.4	19.0	-1.8	-6.5	-7.6	-8.3

- trade deficit with China rising very rapidly
- data for 2023-24 extrapolated based on actuals upto December 2023

Export volume – India versus China

Export volume – II	iulu versus	China	Volume: bn units
	2022	2023	Growth
India	5.85	4.67	-20.2%
China	28.66	29.23	2.0%

Profit and loss standalone



₹ cr

Particulars	2023-24	2022-23	%
Revenue from operations	4,358	5,062	(14%)
Expenditure	3,797	4,366	(13%)
Other income	135	199	(32%)
EBIDTA	696	895	(22%)
EBIDTA %	16%	18%	(2%)
Interest	2	2	-
Depreciation	184	163	13%
PBT	510	730	(30%)
Тах	125	178	(30%)
PAT	385	552	(30%)
RoCE %	13%	19%	
Average capital employed	4,088	3,812	7%

sales volume increased by 5% despite subdued global demand

profit reduced due to price pressure







Profit and loss consolidated



			₹ c
Particulars	2023-24	2022-23	%
Revenue from operations	4,726	5,428	(13%)
Expenditure	4,089	4,653	(12%)
Other income	58	115	(50%)
EBIDTA	695	890	(22%)
EBIDTA %	15%	16%	(1%)
Interest	11	8	(38%)
Depreciation	243	198	(23%)
PBT before share of associate and JV	441	684	(36%)
Share of associate and JV	10	4	150%
Profit before tax	451	688	(34%)
Тах	127	181	(30%)
РАТ	324	507	(36%)
RoCE %	12%	19%	
Average capital employed	3,879	3,545	9%

- depreciation higher due to increased capitalisation
- expenditure decrease in line with sales

Segment results consolidated



₹ cr

Darticularo	Life	science chem	icals	Performance and other chemicals		
Particulars	2023-24	2022-23	lnc (dec) %	2023-24	2022-23	Inc (dec) %
Net revenues from operations*	1,427	1,959	(27%)	3,453	3,706	(7%)
Earnings before interest and tax	203	423	(52%)	240	240	-
EBIT %	14%	22%	-	7%	7%	-
Segment net capital employed	981	1,044	(6%)	2,747	2,722	1%
RoCE %	21%	40%	-	9%	9%	-

* including inter-segment transfers

- LSC performance declined due to lower selling price of products of sub-segments; Crop protection
- P&OC performance declined due to very low demand of products of sub-segments; Colors, Polymers and Bulk chemicals

Working capital consolidated



₹ cr

Particulars	Mar 24	Mar 23	Inc (dec)
Inventories	650	820	(170)
Debtors	927	845	82
Other current assets	271	236	35
Gross working capital* (A)	1,848	1,901	(53)
Current liabilities (B)	776	722	54
Net working capital (A-B)	1,072	1,179	(107)

* excluding liquid investment and assets held for sale

Cash flow consolidated



Particulars2023-242022-23Profit before tax451688Adjustment for depreciation, finance costs and others223189Share of profit on associate and JV(10)(4)Changes in working capital and others11127Cash generated from operations775900Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capse expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds1220Net cash outflow from investing activities (B)6683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)11Finance cost(12)(8)(12)Dividend paid on equity shares(74)(96)(12)Finance cost(74)(96)(74)Dividend paid on equity shares-24Net cash (used in) flow from financing activities (C)37(258)Net increase (decrease) in cash and cash equivalents (A+B+C)22(20)			₹ cr
Adjustment for depreciation, finance costs and others223189Share of profit on associate and JV(10)(4)Changes in working capital and others11127Cash generated from operations775900Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption J (Investments) in equity, bonds and alternate funds16(12)Redemption J (Investments) of treasury funds(216)369Repayments J (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements J (repayment) of term loan J working capital loans J current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) J flow from financing activities (C)37(258)	Particulars	2023-24	2022-23
Share of profit on associate and JV(10)(4)Changes in working capital and others11127Cash generated from operations775900Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Profit before tax	451	688
Changes in working capital and others11127Cash generated from operations775900Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(12)(8)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Adjustment for depreciation, finance costs and others	223	189
Cash generated from operations775900Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of treasury funds16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(12)(8)Finance cost(12)(8)Dividend paid on equity shares74(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Share of profit on associate and JV	(10)	(4)
Income tax paid net of refunds(107)(193)Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares-24Net cash (used in) flow from financing activities (C)37(258)	Changes in working capital and others	111	27
Net cash inflow from operating activities (A)668707Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares-24Net cash (used in) flow from financing activities (C)37(258)	Cash generated from operations	775	900
Capex expenditure(496)(852)Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Income tax paid net of refunds	(107)	(193)
Redemption (Investments) in equity, bonds and alternate funds16(12)Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Net cash inflow from operating activities (A)	668	707
Redemption (Investments) of treasury funds(216)369Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Capex expenditure	(496)	(852)
Repayments (disbursements) of loans given16Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Redemption (Investments) in equity, bonds and alternate funds	16	(12)
Interest and dividend received1220Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Redemption (Investments) of treasury funds	(216)	369
Net cash outflow from investing activities (B)(683)(469)Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Repayments (disbursements) of loans given	1	6
Loan disbursements (repayment) of term loan working capital loans current borrowings185(91)Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Interest and dividend received	12	20
Buy back of equity shares(62)(87)Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Net cash outflow from investing activities (B)	(683)	(469)
Finance cost(12)(8)Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Loan disbursements (repayment) of term loan working capital loans current borrowings	185	(91)
Dividend paid on equity shares(74)(96)Transaction with non-controlling interests-24Net cash (used in) flow from financing activities (C)37(258)	Buy back of equity shares	(62)	(87)
Transaction with non-controlling interests - 24 Net cash (used in) flow from financing activities (C) 37 (258)	Finance cost	(12)	(8)
Net cash (used in) flow from financing activities (C)37(258)	Dividend paid on equity shares	(74)	(96)
	Transaction with non-controlling interests	-/	24
Net increase (decrease) in cash and cash equivalents (A+B+C) 22 (20)	Net cash (used in) flow from financing activities (C)	37	(258)
	Net increase (decrease) in cash and cash equivalents (A+B+C)	22	(20)

• working capital improved by ₹ 107 cr

Performance and other chemicals Life science chemicals



Sub segment: Aromatics


Product groups: Intermediates and API intermediates

Serving: Chemical additives, Fragrance, Personal care and Pharmaceutical industries

Product	Market share (2023-24)	Competition
p-Cresol	48%	Asia (3), North America (1)
p-Cd	34%	Asia (2), India (2)
p-AA	80%	India (3) Asia (1) Europe (1)
p-AAI	83%	India (2)
	products: 40 custor	mers: 413
	6 - 6 - 6 - F	



Aromatics



End user industry prospects

	Additives	Fragrance	Personal care
World, \$ bn	4	14	30
CAGR	5%	3.8%	5%
India, \$ mn	37	680	695
CAGR	5%	5%	5-6%

Source: Customer interactions | market reports

Unrealised CAPEX



unrealised sales potential: ₹ 240 cr

Way forward

- implement projects for (3) downstream products (specialty chemicals)
- commercialise (2) products developed in Kilo lab (fragrance)



Performance and other chemicals


Sub segment: Bulk Chemicals and Intermediates

Product groups: Bulk chemicals, Adhesion promoters, Intermediates Industries served: Cosmetics, Chemical, Dyestuff and Tyre

Product	Market share (2023-24)	Competition	
Resorcinol	Significant (India) Insignificant (World)	Asia (4)	
Resorcinol Formaldehyde Resins	Significant (India) Insignificant (World)	India (2), Asia (5)	
1,3-CHD	Significant (India) Significant (World)	India (1), Asia (3)	
	products: 23 customers: 261		



Bulk Chemicals and Intermediates



End user industry prospects



2023 2024 2025 2026 2027 2028 2029

Relevant products: Resorcinol and RF resins Source: Global tire (tyre) market size, share and forecast 2023-2029 – Imarc group

Unrealised CAPEX




unrealised sales potential (intermediate): ₹ 60 cr

Way forward

- add chlorine, hydrogen and sulphuric acid downstream value added products
- increase share of RF resins with key customers

atul

Atul Products Ltd



Unrealised CAPEX




unrealised sales potential: ₹ 485 cr

- stabilise manufacturing operations
- reach full capacity utilisation



Anaven LLP



* excluding 2,75,000 tpa consumed in-situ for manufacture of Glyphosate in China

Unrealised CAPEX



unrealised sales potential: ₹ 123 cr

- increase market share in India
- optimise operating cost
- introduce downstream products



Performance and other chemicals

Sub segment: Colors

Product groups: Textile dyes, Pigments

Industries served: Textile, Paint and Coatings and Paper


Product group	Market share (2023-24)	Competition
Textile dyes – Vat	Significant (India) Significant (World)	India (15), Asia (>15), Rest of world(>6)
Textile dyes – Sulphur black	Significant (India) Insignificant (World)	India (14), Asia (>11), Rest of world (>4)
Textile dyes – other	Insignificant (India) Insignificant (World)	India (>100), Asia (>100), Rest of world (>20)
HP pigments	Insignificant (World)	India (5), Rest of world (>12)
	products: 488 customers:	298



Colors



Unrealised CAPEX




- increase capacity utilisation
- expand product range in reactive and disperse dyes
- develop newer applications for existing products
- broaden market reach in new geographies



unrealised sales potential: ₹ 400 cr




Rudolf Atul Chemicals Ltd



End user industry prospects

US\$ bn



Plant

- aim to move from top 10 to top 3 textile chemical companies in India in next 5 years
- focus on package promotion in denim | printing | yarn with Colors business
- strengthen product portfolio in synthetic fiber segment



Life science chemicals

Sub segment: Crop Protection – Bulk actives


Product groups: Herbicides, Insecticides and Fungicides

Industries served: agriculture and public health

Product	Market share* (2023-24)	Competition
2,4-D and downstream products	10%	Australia (1), Asia (6), Europe (1), North America (1), South America (1)
Indoxacarb	12%	Asia (2), USA (1)
products: 34	formulations	s: 43 customers: 220
* world		



Crop Protection – Bulk Actives



Unrealised CAPEX



unrealised sales potential: ~₹ 100 cr

B.3 bn people by 2030

End user industry prospects

agriculture and allied businesses remain attractive

- launch new products and formulations
- expand regulatory approval footprint
- integrate vertically



Life science chemicals

Sub segment: Crop Protection – Retail

Product groups: Herbicides, Insecticides, Fungicides, Biostimulants and adjuvants

Industries served: agriculture

Brand	Market share* (2023-24)	Competition
Zura	24%	Dhanuka, Meghmani, Adama
Salix	28%	Dhanuka, Meghmani, Adama
Cyno	34%	Corteva
Amsac	18%	Gharda
Rhyzo	16%	Rallis, Parijat
	brands: 63	customers: 1,700
* domestic		



Crop Protection – Retail




New patented formulation



sales potential: ~ ₹ 100 cr

End user industry prospects



agriculture and allied businesses would remain attractive for a long time

- continue to develop patented novel formulations
- organic growth of existing portfolio
- widening the portfolio by way of enhanced cooperations
- optimise channel strength



Brands





Life science chemicals

Sub segment: Pharmaceuticals

Product groups: APIs and API intermediates

Industries served: Pharmaceutical


Product group	Market share (2023-24)	Competition
APIs and API intermediates	Insignificant (world)	India, Asia, Europe, North America
Dapsone	50%	India, Europe
Phosgene chemicals	Insignificant (world)	Asia, Europe, North America

products: 90

customers: 200



Pharmaceuticals



28% 23% Europe 38% Asia-Pacific 2022 A: \$ 58 bn North America 2022 A: \$46 bn 2030 P: \$ 91 bn 2022 A: \$78 bp/ 2030 P: \$75 bn 2030 P: \$ 125 bn 11% Global API market LAMEA 2022 A: \$ 205 bn 2022 A: \$ 23 bn 2030 P: \$ 325 bn 2030 P: \$34 bn CAGR: ~ 6.2% © 2009 www.outline-world-map.com A: Actual P: Projected Source: www.precedenceresearch.com/active-pharmaceutical-ingredient-market

End user industry prospects

Unrealised CAPEX



unrealised sales potential: ₹ 100 cr

- increase sales of (12) APIs
- increase sales of (8) new intermediates
- qualify (7) new products
- expedite customer approvals
- file (12) DMFs
- increase CMO business with strategic customers
- clear USFDA | EDQM audit of ABL-2 scheduled in May 2024



Performance and other chemicals

Sub segment: Polymers – Performance materials

Product groups: Epoxy resins, Curing agents, Reactive diluents, Accelerators and Sulfones

Industries served: Adhesives, Aerospace and Defence, Automotive, Composites, Construction, Electrical and electronics, Marine, Paint and coating, Sport and leisure and Wind energy

Product group	Market share (2023-24)	Competition
Epoxy Resins Curing agents	Significant (India)	India (3), Asia, Europe, North America
Reactive diluents	Significant (India)	India (2), Asia, Europe, North America
Sulfones	Significant (World)	India (3), Asia, North America



Polymers – Performance materials



Unrealised CAPEX

- commission liquid epoxy resins 50,000 TPA plant in 2024-25
- increase reactive diluents and specialty resins capacity
- improve market share in wind blade application
- introduce new products beyond epoxy resins



unrealised sales potential: ₹ 104 cr

atul

Polymers – Retail

Product groups: synthetic rubber based adhesives, polyurethane adhesives, epoxy adhesives and sealants, cyanoacrylates and maintenance spray

Industries served: footwear, mattresses, foam and furnishing, construction, automobile and household

Brand		Market share* (2023-24)	Competition
Lapox		7%	Araldite, Bondtite,
Polygrip		5%	Fevicol, Henkel, Bostik,
Lacare		1%	WD40, Rustolene, Rustlick
	brands: 3	formulations: 164	customers: 550
* domestic			



Polymers – Retail



End user industry prospects

	LAPOX [•]	polygrip	LACARE®	
	ероху	SR, SBS and PU	maintenance	
India, \$ mn	150	415	25	
CAGR	8%	9%	8%	

Offering solutions

an



construction



bangles and handicraft

stone processing







HVAC insulation

footwear

foam and

furnishing



automobiles

service centers





- expand route to market in India
- grow outside of India
- introduce new products and formulations



Brands




LAPOX ULTRABOND ULTRABOND

Polygrip


Lapox and Lacare



Sub segment: Floras




Market reach



		(lakh hectares)
Year	World area harvested (lakh ha)	% increase decrease
2013	11.56	
2014	11.52	-0.35
2015	11.23	-2.52
2016	11.83	5.34
2017	11.88	0.42
2018	12.43	4.63
2019	12.83	3.22
2020	12.58	-1.95
2021	12.62	0.32
2022	12.70	
(0		0.02

(0.01% of total earth land area) (India 0.06 L ha) 0.63

Growth stages



World date palm plantation

Sub-segments overview 54 | 58

Atul Rajasthan Date Palms Ltd



Agriculture scenario

Indicators	India	Global
Agribusiness industry (agriculture, forestry and fisheries)	US\$0.44 bn	US\$3.60 tn
Share of agribusiness in GDP	17.30%	4.40%
Population in 2050 (est)	1.67 bn	10 bn
Rural population in 2022	67%	43%
Employment in agriculture	44%	26.60%
Cropland per capita	0.12 ha	0.20 ha
Water stressed lands	66.60%	18.60%
Hungry population	190 million	770 million
Undernourished	16.60%	9%
Stunted growth in children below 5 years age	31%	22%
Average dietary energy supply	2,594 kCal	2,963 kCal
Prevalence of anemia among women (age: 15 to 49 years)	53%	
Food imports	US\$18.85 bn	
Date imports	4,39,477 MT	



DPD Ltd, UK (Expansion)







Phase – 2







Valsad Institute of Medical Sciences Ltd



3D view of architect



Actual construction of proposed 200 bed Super Speciality hospital at Valsad (under implementation)



Atul Ltd

Atul 396 020, Gujarat

India

investors@atul.co.in | (+91 2632) 230000